Back to Search Start Over

In Vitro Anti-cancer Activity of Adipose-Derived Mesenchymal Stem Cells Increased after Infection with Oncolytic Reovirus

Authors :
Abouzar Babaei
Hossein Bannazadeh Baghi
Akram Nezhadi
Zahra Jamalpoor
Source :
Advanced Pharmaceutical Bulletin, Vol 11, Iss 2, Pp 361-370 (2021)
Publication Year :
2021
Publisher :
Tabriz University of Medical Sciences, 2021.

Abstract

Purpose: Reovirus type 3 Dearing (ReoT3D), a wild type oncolytic virus (OV) from the Reoviridae family, kills KRAS mutant cancer cells. However, the use of OVs has faced with some limitations such as immune responses, and delivery of OVs to the tumor sites in systemic therapy. To solve this, and also to increase the anti-cancer effects of these OVs, mesenchymal stem cells (MSCs) might be used as an effective vehicle for OVs delivery. In this study, we examined the anti-cancer effects of human adipose derived-MSCs (AD-MSCs) as a vehicle of ReoT3D against human glioblastoma cells. Methods: Here, AD-MSCs were characterized and toxicity of ReoT3D on them was determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Then, capability of AD-MSCs for virus production was assessed by real-time polymerase chain reaction (PCR), and different in vitro anti-cancer experiments were applied for our anti-cancer purposes. Results: Our results from toxicity assay revealed that the isolated and provoked AD-MSCs were resistant to nontoxic concentration multiplicity of infection (MOI) >1 pfu/cells of ReoT3D. In addition, the results indicated that AD-MSCs were susceptible for virus life cycle complementation and were capable for production of virus progenies. Furthermore, our results showed that AD-MSCs had oncolysis effects and increased the anti-cancer effects of ReoT3D. Conclusion: AD-MSCs as a susceptible host for oncolytic reovirus could increase the anti-cancer activity of this OV against glioblastoma multiforme (GBM) cell line.

Details

Language :
English
ISSN :
22285881, 22517308, and 89738802
Volume :
11
Issue :
2
Database :
Directory of Open Access Journals
Journal :
Advanced Pharmaceutical Bulletin
Publication Type :
Academic Journal
Accession number :
edsdoj.8973880282d346bb937cbd312101e82a
Document Type :
article
Full Text :
https://doi.org/10.34172/apb.2021.034